Genmab A/S Announces Financial Results for the First Quarter 2012

COPENHAGEN K, Denmark, May 15, 2012 (GLOBE NEWSWIRE) -- "We have achieved a number of business milestones during the last months including the filing of the New Drug Application (NDA) in Japan for ofatumumab and another milestone in our Lundbeck collaboration. We also continue to focus on resources and in the first quarter of the year we have improved the operating result and lowered operating expenses compared to the same period last year," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.